Detalles de la búsqueda
1.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
N Engl J Med
; 389(6): 514-526, 2023 Aug 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37366315
2.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Lancet
; 402(10401): 529-544, 2023 08 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37385280
3.
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
Lancet
; 400(10366): 1869-1881, 2022 11 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-36354040
4.
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
Diabetes Obes Metab
; 22(6): 938-946, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31984598
5.
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Lancet
; 392(10160): 2180-2193, 2018 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-30293770
6.
Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.
Diabetes Obes Metab
; 21(11): 2570-2575, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31364266
7.
Improvements in post-challenge lipid response following tirzepatide treatment in patients with type 2 diabetes.
Diabetes Obes Metab
; 26(2): 785-789, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37989596
8.
Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin.
Diabetes Obes Metab
; 21(9): 2048-2057, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31050143
9.
The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying.
Diabetes Obes Metab
; 25(9): 2784-2788, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37311727
10.
Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.
Diabetes Obes Metab
; 20(6): 1490-1498, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29377522
11.
Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
Diabetes Obes Metab
; 19(7): 1024-1031, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28294499
12.
Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.
Lancet
; 385(9982): 2057-66, 2015 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-26009229
13.
Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.
Diabetes Obes Metab
; 18(10): 999-1005, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27279266
14.
New improved radiometabolite analysis method for [18F]FTHA from human plasma: a test-retest study with postprandial and fasting state.
EJNMMI Res
; 14(1): 53, 2024 Jun 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38869780
15.
Effects of Tirzepatide vs Semaglutide on ß-cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test.
J Clin Endocrinol Metab
; 2024 May 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38795393
16.
Response to the comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 trials".
Diabetes Obes Metab
; 20(9): 2319-2320, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29781106
17.
P2RY12 gene polymorphisms and effect of clopidogrel on platelet aggregation.
Coll Antropol
; 37(2): 491-8, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23940995
18.
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.
Diabetes Care
; 46(5): 998-1004, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36857477
19.
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Lancet Diabetes Endocrinol
; 10(6): 418-429, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35468322
20.
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Cell Metab
; 34(9): 1234-1247.e9, 2022 09 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35985340